Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

Executive Summary

AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.

Advertisement

Related Content

"Synergy Search" Lies Behind AZ's Combined CV, Diabetes and Renal Ops
Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Brilinta No Better Than Aspirin In Stroke Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel